Articles dans des revues avec comité de lecture (128)
  1. 34. Dirix, V., Collart, P., Van Praet, A., Hites, M., Dauby, N., Allard, S., Racapé, J., Singh, M., Locht, C., Mascart, F., & Corbiere, V. (2022). Immuno-Diagnosis of Active Tuberculosis by a Combination of Cytokines/Chemokines Induced by Two Stage-Specific Mycobacterial Antigens: A Pilot Study in a Low TB Incidence Country. Frontiers in immunology, 13, 842604. doi:10.3389/fimmu.2022.842604
  2. 35. Martin, C., Florence, E., Domingo, C., Delforge, M.-L., De Wit, S., & Dauby, N. (2022). Seroconversion and antibody persistence after yellow fever vaccination in people living with HIV: impact of baseline HIV viral load and yellow fever seropositivity. Journal of travel medicine. doi:10.1093/jtm/taac024
  3. 36. Ponthieux, F., Dauby, N., Maillart, E., Fils, J.-F., Smet, J., Claus, M., Besse-Hammer, T., De Bels, D., Corazza, F., & Nagant, C. (2022). Tocilizumab-Induced Unexpected Increase of Several Inflammatory Cytokines in Critically Ill COVID-19 Patients: The Anti-Inflammatory Side of IL-6. Viral immunology. doi:10.1089/vim.2021.0111
  4. 37. Karakike, E., Scicluna, B. B., Roumpoutsou, M., Mitrou, I., Karampela, N., Karageorgos, A., Psaroulis, K., Massa, E., Pitsoulis, A., Chaloulis, P., Pappa, E., Schrijver, I. I., Frantzeskaki, N., Lada, M., Dauby, N., De Bels, D., Floros, I., Anisoglou, S., Antoniadou, E., Patrani, M., Vlachogianni, G., Mouloudi, E., Antoniadou, A., Grimaldi, D., Roger, T., Wiersinga, W. J., Tsangaris, I., & Giamarellos-Bourboulis, E. J. (2022). Effect of intravenous clarithromycin in patients with sepsis, respiratory and multiple organ dysfunction syndrome: a randomized clinical trial. Critical care, 26(1), 183. doi:10.1186/s13054-022-04055-4
  5. 38. Cupaiolo, R., Cherkaoui, S., Serrano, G., Dauby, N., Georgala, A., Blumental, S., Maillart, E., Hites, M., Hallin, M., & Martiny, D. (2022). Antimicrobial susceptibility testing determined by Alfred 60/AST (Alifax®) in a multi-sites lab: performance's evaluation and optimization of workflow. Journal of microbiological methods, 194, 106433. doi:10.1016/j.mimet.2022.106433
  6. 39. Dauby, N. (2021). Re: 'ESCMID COVID-19 living guidelines: drug treatment and clinical management' by Bartoletti et al. Clinical microbiology and infection. doi:10.1016/j.cmi.2021.11.026
  7. 40. Dethioux, L., Dauby, N., Montesinos Hernandez, I., Rebuffat, E., & Hainaut, M. (2021). SARS-CoV-2 seroprevalence in children and their family members, July–October 2020, Brussels. European journal of pediatrics. doi:10.1007/s00431-021-04284-9
  8. 41. Subissi, L., Bossuyt, N., Reynders, M., Gerard, M., Dauby, N., Lacor, P., Daelemans, S., Lissoir, B., Holemans, X., Magerman, K., Jouck, D., Bourgeois, M., Delaere, B., Quoilin, S., Van Gucht, S., Thomas, I., & Barbezange, C. (2021). Extending influenza surveillance to detect non-influenza respiratory viruses of public health relevance: analysis of surveillance data, 2015-2019, Belgium. Eurosurveillance, 38. doi:10.2807/1560-7917.ES.2021.26.38.2001104
  9. 42. moretti, M., Allard, S. D., Dauby, N., De Geyter, D., Mahadeb, B., Miendje Deyi, Y. V., Balti, E. E., & Clevenbergh, P. A. (2021). Clinical features of Legionnaires’ disease at three Belgian university hospitals, a retrospective study. Acta Clinica Belgica (English ed. Printed), 1-7. doi:10.1080/17843286.2021.1978211
  10. 43. Subissi, L., Bossuyt, N., Reynders, M., Gerard, M., Dauby, N., Lacor, P., Daelemans, S., Lissoir, B., Holemans, X., Magerman, K., Jouck, D., Bourgeois, M., Delaere, B., Quoilin, S., van Gucht, S., Thomas, I., & Barbezange, C. (2021). Spotlight influenza: Extending influenza surveillance to detect non-influenza respiratory viruses of public health relevance: Analysis of surveillance data, Belgium, 2015 to 2019. Euro surveillance, 26(38), 1-10. doi:10.2807/1560-7917.ES.2021.26.38.2001104
  11. 44. Montesinos Hernandez, I., Dahma, H., Wolff, F., Dauby, N., Delaunoy, S., Wuyts, M., Detemmerman, C., Duterme, C., Vandenberg, O., Martin, C., & Hallin, M. (2021). Neutralizing antibody responses following natural SARS-CoV-2 infection: dynamics and correlation with commercial serologic tests. Journal of clinical virology, 104988. doi:10.1016/j.jcv.2021.104988
  12. 45. Bastard, P., Dauby, N., Goffard, J.-C., Vandernoot, I., et al. (2021). Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Science immunology, 6(62), eabl4340. doi:10.1126/sciimmunol.abl4340
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Suivant >>